摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)methyl methanesulfonate

中文名称
——
中文别名
——
英文名称
(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)methyl methanesulfonate
英文别名
6-Chloro-1,2-dihydro-3-methanesulfonyloxymethyl-2-methyl-1-oxo-4-phenylisoquinoline;(6-Chloro-2-methyl-1-oxo-4-phenylisoquinolin-3-yl)methyl methanesulfonate
(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)methyl methanesulfonate化学式
CAS
——
化学式
C18H16ClNO4S
mdl
——
分子量
377.848
InChiKey
GOJGVFVINYMDHZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    72.1
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)methyl methanesulfonate盐酸 、 sodium hydride 、 溶剂黄146 作用下, 以 四氢呋喃 为溶剂, 反应 50.0h, 生成 3-(6-chloro-2-methyl-1-oxo-4-phenyl-1,2-dihydroisoquinolin-3-yl)propanoic acid
    参考文献:
    名称:
    Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
    摘要:
    The design, synthesis, and structure-activity relationships of a new class of potent and orally active non-peptide dipeptidyl peptidase IV (DPP-4) inhibitors, 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones, are described. We hypothesized that the 4-phenyl group of the isoquinolone occupies the S1 pocket of the enzyme, the 3-aminomethyl group forms an electrostatic interaction with the S2 pocket, and the introduction of a hydrogen bond donor onto the 6- or 7-substituent provides interaction with the hydrophilic region of the enzyme. Based on this hypothesis, intensive research focused on developing new non-peptide DPP-4 inhibitors has been carried out. Among the compounds designed in this study, we identified 2-[(3-aminomethyl-2-(2-methylpropyl)-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinyl) oxy] acetamide (35a) as a potent, selective, and orally bioavailable DPP-4 inhibitor, which exhibited in vivo efficacy in diabetic model rats. Finally, X-ray crystallography of 35a in a complex with the enzyme validated our hypothesized binding mode and identified Lys554 as a new target-binding site available for DPP-4 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.06.059
  • 作为产物:
    参考文献:
    名称:
    Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
    摘要:
    The design, synthesis, and structure-activity relationships of a new class of potent and orally active non-peptide dipeptidyl peptidase IV (DPP-4) inhibitors, 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones, are described. We hypothesized that the 4-phenyl group of the isoquinolone occupies the S1 pocket of the enzyme, the 3-aminomethyl group forms an electrostatic interaction with the S2 pocket, and the introduction of a hydrogen bond donor onto the 6- or 7-substituent provides interaction with the hydrophilic region of the enzyme. Based on this hypothesis, intensive research focused on developing new non-peptide DPP-4 inhibitors has been carried out. Among the compounds designed in this study, we identified 2-[(3-aminomethyl-2-(2-methylpropyl)-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinyl) oxy] acetamide (35a) as a potent, selective, and orally bioavailable DPP-4 inhibitor, which exhibited in vivo efficacy in diabetic model rats. Finally, X-ray crystallography of 35a in a complex with the enzyme validated our hypothesized binding mode and identified Lys554 as a new target-binding site available for DPP-4 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2011.06.059
点击查看最新优质反应信息

文献信息

  • Condensed heterocyclic compounds, their production and use
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:EP0585913A2
    公开(公告)日:1994-03-09
    Novel compound represented by the formula: wherein ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR¹- (R¹ represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS- or -C(R²)R2a- (R² and R2a independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR³- (R³ represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group , an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally substituted hydrocarbon group); ........ represents a single or double bond; when ........ is a single bond, Z represents -CR⁴- (R⁴ represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when ........ is a double bond, Z represents a carbon atom; D represents a C₁₋₃ alkylene group which may be substituted by an oxo group or a thioxo group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thioxo group; E represents -NR⁵- (R⁵ represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)n- (n is 0,1 or 2), or R⁵ and Y, taken together, may form a 5- to 7- membered ring which may be substituted by an oxo group or a thioxo group; G represents a bond or a C₁₋₃ alkylene group; Ar represents an optionally substituted aryl group or an optionally substituted heterocyclic group, provided that (1) when (i) -X-Y- represents - O-CO- or -CO-O-, (ii) D represents -CO- and (iii) E represents -NR⁵-, either (a) G represents a C₁₋₃ alkylene group and Ar represents a substituted aryl group or a substituted heterocyclic group, or (b) G represents a bond and R⁵ represents an optionally substituted hydrocarbon group, and (2) when -X-Y- represents -NH-CO-, D represents -CO-, or a salt thereof having an excellent activity of inhibiting ACAT, lowering chlesterol in blood and inhibiting tachykinin recepter, or a salt thereof, their production and use.
    由式表示的新型化合物: 其中环 A 可被取代 环 B 代表任选取代的苯环; X或Y代表-NR¹-(R¹代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基)、-O-或-S-,另一个代表-CO-、-CS-或-C(R²)R2a-(R²和R2a独立地代表氢原子或任选取代的烃基)、或 X 或 Y 代表-N=,另一个代表 =CR³-(R³ 代表氢原子、卤素原子、任选取代的烃基、任选取代的氨基、取代的羟基或被任选取代的烃基取代的巯基); ........ 代表单键或双键; 当 ........ 为单键时,Z 代表-CR⁴-(R⁴ 代表氢原子、羟基或任选取代的烃基)或氮原子;或 (ii) 当 ........ 为双键时,Z 代表碳原子; D 代表可被氧代基团或硫代基团取代的 C₁₋₃亚烷基,或 D 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 元环; E 代表-NR⁵-(R⁵ 代表氢原子或任选取代的烃基)、-O-或-S(O)n-(n 为 0、1 或 2),或 R⁵ 和 Y 合在一起可形成可被氧代基团或硫代基团取代的 5-7 分子环; G 代表键或 C₁₋₃ 亚烷基; Ar 代表任选取代的芳基或任选取代的杂环基,条件是 (1) 当(i)-X-Y-代表-O-CO-或-CO-O-,(ii)D 代表-CO-和(iii)E 代表-NR⁵-时, (a) G 代表 C₁₋₃亚烷基,Ar 代表取代的芳基或取代的杂环基、(2) 当-X-Y-代表-NH-CO-时,D代表-CO-,或其盐具有抑制 ACAT、降低血液中胆固醇和抑制速激肽受体的优异活性,或其盐的生产和使用。
  • Isochinolinone derivatives, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP0634402A1
    公开(公告)日:1995-01-18
    Novel compounds represented by the formula: wherein the ring A and the ring B each stand for an optionally substituted benzene ring; Ar stands for an optionally substituted aryl group or an optionally substituted heterocyclic group; Q stands for an oxygen atom or a sulfur atom; R stands for a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group; X stands for -O- or -NR¹- wherein R¹ stands for a hydrogen atom or an optionally substituted hydrocarbon group; Y stands for -O-, -NR²- wherein R² stands for a hydrogen atom or an optionally substituted hydrocarbon group, or a bond; m denotes 1, 2 or 3, and n denotes 0, 1 or 2, and salts thereof which have an excellent calcium- or substance P receptor-antagonistic activity, being useful for treating a cerebralvascular disorder in mammals such as cerebralischemia, cerebral edema and neuronal damage, their production and use.
    式所代表的新型化合物: 其中环 A 和环 B 各代表一个任选取代的苯环; Ar 代表任选取代的芳基或任选取代的杂环基团; Q 代表氧原子或硫原子; R 代表氢原子、任选取代的烃基、任选取代的羟基或任选取代的氨基; X 代表-O-或-NR¹-,其中 R¹ 代表氢原子或任选取代的烃基; Y 代表-O-、-NR²-(其中 R² 代表氢原子或任选取代的烃基)或键; m 表示 1、2 或 3,以及 n 表示 0、1 或 2,及其盐类,它们具有优异的钙或 P 物质受体拮抗活性,可用于治疗哺乳动物的脑血管疾病,如脑缺血、脑水肿和神经元损伤。
  • US5482967A
    申请人:——
    公开号:US5482967A
    公开(公告)日:1996-01-09
  • US5527811A
    申请人:——
    公开号:US5527811A
    公开(公告)日:1996-06-18
  • US5700810A
    申请人:——
    公开号:US5700810A
    公开(公告)日:1997-12-23
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-